Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 26, 2022Clinical Research in CardiologyOpen Access

Change in skin sodium content between baseline and 3 months was -1.3 ± 3.5 AU in the empagliflozin group versus 0.6 ± 3.5 AU in the placebo group (p=0.022 for between-group difference).

View Full Paper
Ask AI
Bookmark
Share

Why the study?

SGLT2 inhibitors provide cardiovascular protection in chronic heart failure, prompting the hypothesis that empagliflozin reduces tissue sodium content in these patients.

Does empagliflozin reduce tissue sodium content in patients with chronic heart failure?

Population

74 patients with NYHA class II–III CHF and ejection fraction 49% or less

Comparison

Empagliflozin 10 mg once daily vs placebo

Design

Double-blind, randomised (2:1), placebo-controlled, parallel-group trial

Follow-up

3 months

Authors

JKJulie KolwelterDKDennis KannenkerilPLPeter Linz

Discussion

Loading...

Member takes

Overview

Offers mechanistic rationale for SGLT2i in CHF; confirms tissue sodium reduction hypothesis via RCT.

Structured PICO

Does empagliflozin reduce tissue sodium content in patients with chronic heart failure?

P
Population
74 patients with NYHA class II-III chronic heart failure and an ejection fraction of 49% or less
I
Intervention
Empagliflozin 10 mg once daily for 3 months
C
Comparator
Placebo for 3 months
O
Outcome
Tissue sodium content of the lower leg assessed non-invasively by sodium-MRI (23Na-MRI) at 1 and 3 monthssurrogate

Empagliflozin significantly reduces skin sodium content in patients with chronic heart failure, suggesting a potential mechanism of benefit through reduction of subclinical micro-edema or non-osmotic bound tissue sodium.

Cite This Study

Kolwelter et al. (2022) studied this question.

synapsesocial.com/papers/6a87a502cc0e5f225b975202https://doi.org/10.1007/s00392-022-02119-7
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial2021 · 355 citations
  2. 2Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis2021 · 38 citations
  3. 3Increased myocardial sodium signal intensity in Conn’s syndrome detected by 23Na magnetic resonance imaging2018 · 38 citations
  4. 4Heart Failure with Preserved and Reduced Ejection Fraction in Hemodialysis Patients: Prevalence, Disease Prediction and Prognosis2017 · 2,816 citations
  5. 5Glycosaminoglycan polymerization may enable osmotically inactive Na+storage in the skin2004 · 334 citations